API industries surges ahead: eXinvest of Emirates position in the market
eXinvest of Emirates is an active partner is API’s supply. With a worldwide network of producers, the company is stable supply Brands and alternative producers of the most important API.
The active pharmaceutical ingredients industry is projected to reach USD 198.39 billion by 2030 from USD 144.20 billion in 2025.
That is a CAGR of 6.6%—driven by increased R&D funding, outsourcing of API manufacturing, and rising healthcare spend.
API manufacturing is complex, margins are tight, and production costs are high.
Despite these challenges, a handful of global giants dominate the landscape.
→ Pfizer: Leading with its CentreOne business, backed by a global footprint and strong distribution.
→ Teva: With over 350 API products, it holds one of the broadest portfolios in the market.
→ GSK: Innovating with sustainable API manufacturing to lower environmental strain.
→ Sanofi: Spinning off EUROAPI to build Europe’s API independence and strengthen partnerships.
→ Viatris: Offering APIs across 100+ countries with 50 manufacturing facilities worldwide.
These companies are not just competing.
They are shaping the future of medicine at the foundation level—the ingredients every therapy depends on.
Ask for our proposals and projects to:
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.eXinvest.ae
www.finchemo.com
